Table 1.

Characteristics and clinical symptoms of the study population (N = 52).

	Group 1 (n = 27)	Group 2 (n = 16)	Group 3 (n = 9)	p-Value
Gender (M)	16 (17.1%)	7 (25.0%)	5 (17.9%)	0.567
Contact with COVID-19 positive	17 (63.0%)	1 (6.3%)	0 (0.0%)	0.000
Cardiopathy	0 (0.0%)	0 (0.0%)	0 (0.0%)	-
Immune deficiency	1 (3.7%)	2 (12.5%)	0 (0.0%)	0.570
Tachycardia	2 (7.4%)	2 (12.5%)	0 (0.0%)	0.640
Tachypnea	0 (0.0%)	0 (0.0%)	0 (0.0%)	-
Fever	19 (70.4%)	16 (100.0%)	0 (0.0%)	0.000
Cough	7 (25.9%)	5 (31.3%)	1 (11.1%)	0.570
Rinitis	4 (14.8%)	0 (0.0%)	0 (0.0%)	0.280
Dyspnea	1 (3.7%)	0 (0.0%)	0 (0.0%)	1.000
Respiratory symptoms	8 (29.6%)	5 (31.3%)	1 (11.1%)	0.588
Rash	2 (28.6%)	4 (57.1%)	1 (14.3%)	0.292
Muscle aches	6 (22.2%)	4 (25.0%)	2 (22.2%)	1.000
Chest pain	3 (11.1%)	0 (0.0%)	1 (11.1%)	0.377
Abdominal Pain	4 (14.8%)	6 (37.5%)	1 (11.1%)	0.232
Vomit	2 (7.4%)	2 (12.5%)	1 (11.1%)	0.838
Diarrhea	3 (11.1%)	2 (12.5%)	0 (0.0%)	0.692
Gastrointestinal symptoms	6 (22.2%)	7 (43.8%)	1 (11.1%)	0.172
Headache	2 (7.4%)	2 (12.5%)	1 (11.1%)	0.838
Asthenia	8 (29.6%)	7 (43.8%)	3 (33.3%)	0.684
Seizures	0 (0.0%)	0 (0.0%)	0 (0.0%)	-
Ageusia	0 (0.0%)	0 (0.0%)	0 (0.0%)	-
Anosmia	2 (7.4%)	0 (0.0%)	0 (0.0%)	0.674
Neurological symptoms	11 (40.7%)	8 (50.0%)	4 (44.4%)	0.929
Lymphadenopathy	3 (11.1%)	3 (18.8%)	0 (0.0%)	0.448
Pharyngodynia	4 (14.8%)	5 (31.3%)	0 (0.0%)	0.140
Conjunctivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	-
Asymptomatic	4 (14.8%)	0 (0.0%)	4 (44.4%)	0.120
Hospitalization	16 (59.3%)	10 (62.5%)	2 (22.2%)	0.131

Data expressed as total numbers and percentage (%); Group 1: children affected by COVID-19; Group 2: febrile children affected by other viral infections; Group 3: children without infections.